Loading stock data…
$224.80+0.98 (+0.44%)
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. in the Healthcare sector is trading at $224.80 with a market capitalization of $30.6B. Wall Street consensus targets $370.55 (26 analysts), implying a +64.8% move over the next 12 months. The stock is currently near its 52-week low of $197.81, remaining 24.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.29B↑ | $1.17B↑ | $1.10B↓ | $1.25B↑ | $773.69M |
| Gross Profit | $992.50M↑ | $956.05M↑ | $829.31M↓ | $1.05B↑ | $630.74M |
| Operating Income | $231.44M↓ | $268.64M↑ | $131.72M↓ | $367.98M↑ | -$16.20M |
| Net Income | $164.49M↓ | $205.99M↑ | $186.42M↓ | $251.08M↑ | -$72.23M |
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediat...